DK2968226T3 - Oxprenololsammensætninger til behandling af cancer - Google Patents
Oxprenololsammensætninger til behandling af cancer Download PDFInfo
- Publication number
- DK2968226T3 DK2968226T3 DK14763752.4T DK14763752T DK2968226T3 DK 2968226 T3 DK2968226 T3 DK 2968226T3 DK 14763752 T DK14763752 T DK 14763752T DK 2968226 T3 DK2968226 T3 DK 2968226T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxprenolol
- cancer
- composition
- individual
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Claims (12)
1. Sammensætning, der omfatter oxprenolol eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandling af levercancer, hvor sammensætningen omfatter et enantiomert overskud af S-oxprenolol.
2. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen administreres til et individ uden symptom på cancerkakeksi.
3. Sammensætning, der omfatter oxprenolol eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandling af cancer, således at overlevelse forlænges, tab af kropsvægt forhindres, livskvalitet forbedres og/eller muskelsvind forebygges og behandles, hvor sammensætningen omfatter et enantiomert overskud af S-oxprenolol.
4. Sammensætning til anvendelse ifølge krav 3, hvor sammensætningen administreres til et individ uden symptom på cancerkakeksi.
5. Sammensætning, der omfatter oxprenolol eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandling af cancerkakeksi, hvor sammensætningen omfatter et enantiomert overskud af S-oxprenolol.
6. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 3 til 5, hvor canceren er valgt fra gruppen bestående af levercancer, lungecancer, pankreascancer, hjernecancer, gastrisk cancer, øsofaguscancer, kolorektal cancer og cancer i hoved og hals.
7. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor sammensætningen omfatter et enantiomert overskud på mindst 10 % S-oxprenolol.
8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor canceren er cancer på et tidligt stadie.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor canceren er en cancer på et sent stadie.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor sammensætningen administreres oralt.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor S-oxprenolol administreres i en mængde af 80 til 160 mg dagligt.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 11, hvor sammensætningen administreres dagligt eller to gange dagligt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361786241P | 2013-03-14 | 2013-03-14 | |
| PCT/AU2014/000266 WO2014138806A1 (en) | 2013-03-14 | 2014-03-14 | Oxprenolol compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2968226T3 true DK2968226T3 (da) | 2018-11-26 |
Family
ID=51535618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14763752.4T DK2968226T3 (da) | 2013-03-14 | 2014-03-14 | Oxprenololsammensætninger til behandling af cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10398658B2 (da) |
| EP (1) | EP2968226B1 (da) |
| CN (2) | CN110169962B (da) |
| AU (1) | AU2014231716B2 (da) |
| CA (1) | CA2906196C (da) |
| CY (1) | CY1120906T1 (da) |
| DK (1) | DK2968226T3 (da) |
| ES (1) | ES2698363T3 (da) |
| HK (1) | HK1220114A1 (da) |
| HR (1) | HRP20182041T1 (da) |
| NZ (1) | NZ713129A (da) |
| PL (1) | PL2968226T3 (da) |
| PT (1) | PT2968226T (da) |
| TW (1) | TWI669113B (da) |
| WO (1) | WO2014138806A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI669113B (zh) | 2013-03-14 | 2019-08-21 | 英商愛迪美治療有限公司 | 用於治療癌症之氧烯洛爾（ｏｘｐｒｅｎｏｌｏｌ）組合物 |
| US20160317062A1 (en) * | 2015-05-01 | 2016-11-03 | Mmtc, Inc. | Wearable microwave radiometer |
| JP7189587B2 (ja) * | 2015-10-30 | 2022-12-14 | 典正 三浦 | メチル化関連酵素ｈａｔ１とｋａｔ８の阻害薬 |
| CA3015313A1 (en) | 2016-02-26 | 2017-08-31 | Actimed Therapeutics Ltd | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness |
| CN112755021A (zh) * | 2021-02-26 | 2021-05-07 | 上海市第十人民医院 | 褪黑素抑制早期肺癌合并多发结节非消融区结节恶变的新用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508118D0 (en) | 1995-04-21 | 1995-06-07 | Rhone Poulenc Ltd | Compounds for use as a chiral stationary phase in enantiomeric separations |
| ATE222231T1 (de) | 1996-09-18 | 2002-08-15 | Daiso Co Ltd | Verfahren zur herstellung von 3-amino-2-hydroxy-1-propylethern |
| EP1121111B1 (en) * | 1998-10-15 | 2010-02-10 | Imperial Innovations Limited | Compounds for the treatment of weight loss |
| US20050143378A1 (en) | 2003-12-29 | 2005-06-30 | Yun Anthony J. | Treatment of conditions through pharmacological modulation of the autonomic nervous system |
| GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| CN101323580A (zh) * | 2008-07-25 | 2008-12-17 | 河北科技大学 | 手性芳氧丙醇胺类化合物及其盐的合成方法 |
| GB0907350D0 (en) * | 2009-04-29 | 2009-06-10 | Myotec Therapeutics Ltd | Methods |
| IN2012DN06588A (da) * | 2010-02-10 | 2015-10-23 | Novartis Ag | |
| WO2012030234A1 (en) * | 2010-09-01 | 2012-03-08 | Swee Thong Tan | Methods and compositions for treating cancer |
| US20120178757A1 (en) * | 2010-12-09 | 2012-07-12 | Nottingham University Hospitals Nhs Trust | Method For The Prevention Of Cancer Metastasis |
| TWI669113B (zh) | 2013-03-14 | 2019-08-21 | 英商愛迪美治療有限公司 | 用於治療癌症之氧烯洛爾（ｏｘｐｒｅｎｏｌｏｌ）組合物 |
-
2014
- 2014-03-14 TW TW103109279A patent/TWI669113B/zh active
- 2014-03-14 CN CN201910535837.9A patent/CN110169962B/zh active Active
- 2014-03-14 NZ NZ713129A patent/NZ713129A/en unknown
- 2014-03-14 PT PT14763752T patent/PT2968226T/pt unknown
- 2014-03-14 EP EP14763752.4A patent/EP2968226B1/en active Active
- 2014-03-14 AU AU2014231716A patent/AU2014231716B2/en active Active
- 2014-03-14 US US14/776,020 patent/US10398658B2/en active Active
- 2014-03-14 WO PCT/AU2014/000266 patent/WO2014138806A1/en active Application Filing
- 2014-03-14 PL PL14763752T patent/PL2968226T3/pl unknown
- 2014-03-14 ES ES14763752T patent/ES2698363T3/es active Active
- 2014-03-14 CN CN201480025225.0A patent/CN105338975B/zh active Active
- 2014-03-14 CA CA2906196A patent/CA2906196C/en active Active
- 2014-03-14 DK DK14763752.4T patent/DK2968226T3/da active
-
2016
- 2016-07-12 HK HK16108117.3A patent/HK1220114A1/zh unknown
-
2018
- 2018-03-16 US US15/923,872 patent/US10828270B2/en active Active
- 2018-10-30 CY CY181101113T patent/CY1120906T1/el unknown
- 2018-12-05 HR HRP20182041TT patent/HRP20182041T1/hr unknown
-
2020
- 2020-10-07 US US17/065,297 patent/US11433036B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10828270B2 (en) | 2020-11-10 |
| CA2906196C (en) | 2021-02-16 |
| TWI669113B (zh) | 2019-08-21 |
| NZ713129A (en) | 2020-03-27 |
| US20190054043A1 (en) | 2019-02-21 |
| US20160022612A1 (en) | 2016-01-28 |
| AU2014231716A1 (en) | 2015-11-05 |
| TW201513850A (zh) | 2015-04-16 |
| HRP20182041T1 (hr) | 2019-02-08 |
| EP2968226B1 (en) | 2018-09-05 |
| PT2968226T (pt) | 2018-11-30 |
| US10398658B2 (en) | 2019-09-03 |
| EP2968226A4 (en) | 2016-10-26 |
| ES2698363T3 (es) | 2019-02-04 |
| AU2014231716B2 (en) | 2018-08-16 |
| CA2906196A1 (en) | 2014-09-18 |
| CN105338975A (zh) | 2016-02-17 |
| HK1220114A1 (zh) | 2017-04-28 |
| EP2968226A1 (en) | 2016-01-20 |
| PL2968226T3 (pl) | 2019-03-29 |
| US11433036B2 (en) | 2022-09-06 |
| WO2014138806A1 (en) | 2014-09-18 |
| US20210251924A1 (en) | 2021-08-19 |
| CN105338975B (zh) | 2019-07-16 |
| CN110169962A (zh) | 2019-08-27 |
| CY1120906T1 (el) | 2019-12-11 |
| CN110169962B (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11433036B2 (en) | Oxprenolol compositions for treating cancer | |
| JP2010514696A (ja) | 心血管症状の低減 | |
| BR112020023204A2 (pt) | composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos | |
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| US20230046317A1 (en) | Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer | |
| AU2022241503A1 (en) | S-enantiomerically enriched compositions of beta blockers for treating muscle weakness | |
| EP2968227B1 (en) | S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis | |
| US20230190768A1 (en) | Combination comprising tricycle compound and use thereof in preparation of medicament for treating hbv | |
| US20150238488A1 (en) | Drug composition for treating tumors and application thereof | |
| WO2020249120A1 (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
| ES2672326T3 (es) | Analogos de tiazolidinona deuterados como agonistas para el receptor de la hormona folículo estimulante | |
| WO2014138802A1 (en) | Canrenoate compositions for treating cancer | |
| US10058618B2 (en) | PAK1-blocking 1,2,3-triazolyl esters | |
| TW202332447A (zh) | 使用ＴＨＲ—β促效劑之肝臟病症之治療 | |
| KR20130045844A (ko) | 아미오다론 중단 직후에 투여하기 위한 약제의 제조를 위한, 드로네다론 또는 이의 제약상 허용되는 염의 용도 | |
| TR201603780A1 (tr) | Sfi̇ngozi̇n-1 fosfat reseptör agoni̇sti̇ i̇çeren formülasyonlar |